Robert Burns
Board member
Board of Directors
Targovax
Norway
Biography
Robert Burns is a consultant and advisor to companies developing immune based therapies in cancer. He has experience over more than 30 years in building biotechnology companies focused on immuno-oncology and was a member of the board of Directors of Oncos prior to the Combination. Dr Burns was previously Chairman of Haemostatix Limited before its acquisition by Ergomed plc. He was also previously CEO at 4-Antibody AG, Affitech A/S (NASDAQ/OMX), and Celldex Therapeutics Inc (NASDAQ), each immuno-oncology immune activator and antibody discovery companies. Prior to Celldex Therapeutics, Dr Burns was Director of Technology Licensing at the Ludwig Institute for Cancer Research, an international independently financed not-for-profit research group focused on cancer immune activators and antibody based cancer immunotherapies. He holds a PhD in Chemistry and is a UK citizen, residing in Oxford, UK.
Research Interest
Biotechnology, immuno-oncology ,antibody discovery, consultant , advisor, chemistry
